CTOs on the Move

Casma Therapeutics

www.casmatx.com

 
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Casma Therapeutics raised $58.5M on 05/03/2018
Casma Therapeutics raised $50M on 09/10/2020

Similar Companies

Kurome Therapeutics

Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.

Glympse Bio

Glympse Bio is developing a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases.

Teknova

Teknova offers custom molecular biology media such as buffers and reagents, pre-poured agar plates, dry culture media, liquid culture media, and media supplements.

Talis Biomedical

Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings.

4C Medical Technologies

4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR).